Page 366 - IJB-10-3

International Journal of Bioprinting hNVU chip for brain modeling and drug screening

50. Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati 58. Baker SJ, Poulikakos PI, Irie HY, Parekh S, Reddy EP. CDK4:
N. Current challenges and opportunities in treating a master regulator of the cell cycle and its role in cancer.
glioblastoma. Pharmacol Rev. 2018;70(3):412-445. Genes Cancer. 2022;25(13):21-45.
doi: 10.1124/pr.117.014944 doi: 10.18632/genesandcancer.221
51. Abudumijiti A, Jianhua Rn, Yuwei Y, et al. Ganoderic acid 59. Fan Y, Peng X, Wang Y, Li B, Zhao G. Comprehensive analysis
improves 5-fluorouracil-induced cognitive dysfunction in of HDAC family identifies HDAC1 as a prognostic and
mice. Food Funct. 2021;12:12325-12337. immune infiltration indicator and HDAC1-related signature
doi: 10.1039/D1FO03055H for prognosis in glioma. Front Mol Biosci. 2021;8:720020.
doi: 10.3389/fmolb.2021.720020
52. Cai YY, Yap CW, Wang Z, et al. Solubilization of vorinostat
by cyclodextrins. J Clin Pharm Ther. 2010;35(5):521-526. 60. Hrzenjak A, Moinfar F, Kremser ML, et al. Histone
doi: 10.1111/j.1365-2710.2009.01095.x deacetylase inhibitor vorinostat suppresses the growth of
uterine sarcomas in vitro and in vivo. Mol Cancer. 2010;9:49.
53. Rompicharla SVK, Trivedi P, Kumari P, et al. Evaluation
of anti-tumor efficacy of vorinostat encapsulated self- doi: 10.1186/1476-4598-9-49
assembled polymeric micelles in solid tumors. AAPS 61. Xu WS, Parmigiani R, Marks P. Histone deacetylase
PharmSciTech. 2018;19(7):3141-3151. inhibitors: molecular mechanisms of action. Oncogene.
doi: 10.1208/s12249-018-1149-2 2007;26:5541-5552.
doi: 10.1038/sj.onc.1210620
54. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late
onset cognitive dysfunction associated with chemotherapy 62. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid,
in women with breast cancer. Cancer. 2010;116(14):3348- a histone deacetylase inhibitor: effects on gene expression
3356. and growth of glioma cells in vitro and in vivo. Clin Cancer
doi: 10.1002/cncr.25098 Res. 2007;13(3):1045-1052.
doi: 10.1158/1078-0432.CCR-06-1261
55. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ,
van Dam FSAM. Change in cognitive function after 63. Kang DW, Hwang WC, Noh YN, et al. Phospholipase
chemotherapy: a prospective longitudinal study in breast D1 is upregulated by vorinostat and confers resistance
cancer patients. J Natl Cancer Inst. 2006;98(23):1742-1745. to vorinostat in glioblastoma. J Cell Physiol. 2021;
doi: 10.1093/jnci/djj470 236(1):549-560.
doi: 10.1002/jcp.29882
56. Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A.
Cognitive effects of chemotherapy in breast cancer patients: a 64. Huang CY, Huang CY, Pai YC, et al. Glucose metabolites
dose‒response study. Psychooncology. 2013;22(7):1517-1527. exert opposing roles in tumor chemoresistance. Front Oncol.
doi: 10.1002/pon.3163 2019;9:1282.
doi: 10.3389/fonc.2019.01282
57. Wang H, Liu Z, Li A, et al. COL4A1 as a novel oncogene
associated with the clinical characteristics of malignancy 65. Miura K, Kinouchi M, Ishida K, et al. 5-FU metabolism
predicts poor prognosis in glioma. Exp Ther Med. in cancer and orally administrable 5-FU drugs. Cancers.
2021;22(5):1224. 2010;2:1717-1730.
doi: 10.3892/etm.2021.10658 doi: 10.3390/cancers2031717

Volume 10 Issue 3 (2024) 358 doi: 10.36922/ijb.1684